|
|
||||||||



Departments of
*
Microbiology and Immunology,
Medicine, and
Cell Biology, Neurobiology and Anatomy, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153; and
Division of Digestive Diseases, Rush University, Chicago, IL 60612
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
in response to TCR stimulation
(7, 8, 9, 10). However, T cells do proliferate in mucosal
organized lymphoid tissue such as Peyers patch, as determined in situ
(10), suggesting that there are local environmental
differences for T cell activation in organized lymphoid tissue and in
diffuse lymphoid tissue such as LP. The Ag-specific response of LP T
cells is down-regulated as a result of impaired signal transduction
through the TCR-CD3 complex (7, 8, 11, 12). The reduced
response of LP T cells in normal individuals might be induced by
locally produced, small, nonprotein molecules with oxidative properties
(13). Furthermore, LP macrophages do not provide
costimulation to T cells for proliferation in response to TCR
stimulation (14). In inflamed intestinal mucosa, as in
Crohns disease, increased numbers of proliferating LP T cells have
been documented (10, 15); proinflammatory cytokines, such
as IL-1
, IL-6, IL-15, IFN-
, and TNF-
, that are not expressed
in normal mucosa are produced in the inflamed mucosa (10, 16), suggesting that LP T cells and macrophages might have been
activated as a result of the loss of normal regulatory mechanisms. Cell death by apoptosis regulates the lymphocyte population and terminates immune responses at sites of Ag exposure. Because LP is constantly exposed to environmental Ags, it is highly possible that lymphoid cells in LP are also regulated by apoptosis, i.e., apoptosis might prevent the activation and clonal expansion of lymphocytes to unharmful environmental Ags. It has been shown that isolated human LP T cells have a tendency to undergo apoptosis in vitro (17, 18, 19). In vitro, upon stimulation of LP T cells with anti-CD2 Ab, the cells underwent apoptosis, which was mediated via the CD95 pathway (17). Interestingly, CD2-mediated apoptosis is reduced in patients with Crohns disease (19), and the resistance of T cells to apoptotic signals is associated with a higher ratio of Bcl-2 to Bax (20). However, no study has yet shown that LP T cells undergo apoptosis in vivo to confirm the physiologic significance of mucosal T cell apoptosis. In this study we determined whether LP lymphocytes (T cells and plasma cells) underwent apoptosis in situ in normal mucosa. As a comparison we also determined the apoptotic status of those cells in the inflamed mucosa of patients with colitis where lymphoid cells should have a higher survival rate. We found that a significant amount of LP lymphocytes underwent apoptosis in normal mucosa and that apoptosis was greatly reduced in mucosal inflammation.
| Materials and Methods |
|---|
|
|
|---|
All subjects had endoscopic examination as part of their
clinical evaluation. All patients with colitis had an established
diagnosis of ulcerative colitis (UC), Crohns disease (CD), or
specific colitis (infectious colitis, ischemic colitis, and radiation
colitis). The diagnosis of colitis was based on a standard clinical,
endoscopic, and histological criteria. All patients with colitis were
symptomatic and had endoscopically and histologically active disease.
Symptoms included abdominal pain (n = 6), diarrhea
(n = 15), hematochezia (n = 10), and
urgency (n = 8). Normal individuals (controls) had
screening endoscopic procedure for colon cancer. None had
gastrointestinal symptoms, and all had normal endoscopic findings. Two
pieces of mucosa (
8 mg) were taken from areas of active inflammation
(in colitis patients) or normal-appearing mucosa (in controls) in the
sigmoid colon. Large fresh colonic specimens from normal mucosa were
also obtained from patients who were having colon cancer surgically
removed. The mucosal tissues used were taken far away from the tumor
and close to the resection margin and were macroscopically and
microscopically normal. The biopsies and part of surgical specimens
were immediately snap-frozen in liquid nitrogen and stored at -80°C,
and parts of the surgical specimens were fixed in ice-cold methanol/PBS
(6/1) solution before paraffin embedding for subsequent analysis. This
study was approved by the institutional review board for safety of
human subjects of Loyola University Stritch School of Medicine and Rush
University.
Determination of T cell apoptosis in situ
Detection of apoptotic cells in paraffin-embedded vs cryopreserved human colonic mucosa. Paraffin sections (5 µm) were deparaffinized in two changes of xylene for 5 min each. Sections were hydrated in an alcohol gradient twice (100, 90, 75, and 50% for 3 min each) and incubated for 5 min in tap water. Endogenous peroxidase was quenched by incubating sections in 0.3% H2O2 in PBS for 10 min. Sections were washed twice for 5 min each time in PBS and incubated in a humidified chamber for 1 h at 37°C with TdT, 0.75 U/µl in TdT buffer (Life Technologies, Gaithersburg, MD) in solution with 100 µM biotin-14-dCTP (Life Technologies). After washing, sections were incubated for 30 min each time at room temperature with streptavidin-HRP diluted 1/300 (Amersham, Uppsala, Sweden). Sections were developed with 3,3-diaminobenzidine (DAB; Sigma, St. Louis, MO), counterstained with methyl green, and dehydrated and mounted. Then they were analyzed by light microscopy. Cryopreserved sections were fixed in 1% formaldehyde in PBS (the PBS used throughout this procedure did not contain potassium), washed, blocked with 0.3% H2O2, and washed again. The frozen sections were then treated exactly as described for the paraffin-embedded tissues starting with the TdT incubation before being evaluated by light microscopy.
Phenotype of apoptotic cells in situ.
TdT end-labeling assay and immunofluorescence assay were used to
determine the phenotypes of apoptotic mucosal cells (21).
Human colonic sections (5 µm) were fixed in 1% formaldehyde for 15
min on ice. The sections were washed three times in PBS (pH 7.4) for 5
min each time at 4°C to remove formaldehyde. Fixed colonic sections
were incubated with 10 µl of a solution containing 0.75 U/µl TdT
(Life Technologies), 1x TdT reaction buffer, and 100 µM
biotin-14-dCTP (Life Technologies) for 1 h at 37°C in humidified
chambers. For negative controls, human colonic sections were incubated
with a similar solution without the TdT enzyme. To detect fragmented
DNA with 3' ends labeled with biotinylated-dCTP, the sections were
incubated for 60 min at room temperature with 40 µg/ml
streptavidin-7-amino-4-methylcoumarin-3-acetic acid (AMCA; Roche,
Carpinteria, CA) in 4x SSC staining buffer containing 0.1% Nonidet
P-40 (v/v; Sigma) and 5% nonfat dry milk. The sections were washed
three times in cold PBS at 4°C between each incubation step. After
incubation with streptavidin-AMCA solution, the sections were incubated
with mouse-anti-human CD3, CD38, or CD68 mAbs for 60 min at room
temperature. The mouse isotype of IgG1
(Sigma) was used as a
control. The FITC-conjugated anti-mouse IgG was used as the
secondary Ab. Immunofluorescence microscopy was performed with a
microscope (Leitz, Rockleigh, NJ) equipped with two different filters
for FITC and AMCA (UV). The microphotographs were taken with either a
35-mm camera (Nikon, Melville, NY) or a digital camera (Optronics,
Goleta, CA). The blue fluorescence representing apoptosis (AMCA) was
converted to red using Magnafire, a digital imaging software
associated with the digital camera. This color conversion was performed
for easy visualization of apoptotic cells against the dark
background.
Quantitation of apoptotic cells
At least two biopsies from each patient were used, and all of them were examined for the presence of apoptosis. The whole tissues of each biopsy were examined. To quantify the number of apoptotic cells, after preview of the section, different fields were photographed randomly, and the total number of CD3+, CD38+, or CD68+ cells and respective apoptotic cells were counted by two investigators blinded to the sample groups. Four to 11 fields/tissue were counted for each subject. Apoptosis was expressed as the mean percentage of apoptotic CD3+, CD38+, or CD68+ cells among all CD3+, CD38+, or CD68+ cells from all counted fields. Because of variable background staining at the margins of tissues, counting was considered unreliable in those areas, and they were excluded from the analysis.
Detecting ssDNA in human colonic mucosa
We followed the procedure exactly as specified in the protocol accompanying Ab to ssDNA (Alexis Biochemicals, San Diego, CA). Briefly, mucosa was removed from resected colon of cancer patients and immediately fixed in ice-cold methanol/PBS (6/1) solution. The tissue and solution were returned to -20°C for 2 days. The fixed tissue was dehydrated in two changes of absolute methanol and two changes of xylene and then embedded in paraffin. Fresh 4-µm sections were prepared before staining and heated at 56°C for 12 h. Sections were deparaffinized in two changes of Safeclear (Fisher, Hanover Park, IL) and incubated in three changes of methanol/PBS (6/1) solution for 20 min each. Then they were rinsed with Dulbeccos PBS (the only PBS used throughout the procedure) and incubated for 5 min in PBS supplemented with 0.2% Triton X-100 and 5 mM MgCl2. Sections were then heated for exactly 6.5 min in a 99°C water bath followed by placement in ice-cold PBS for 10 min. As a negative control, sections were incubated with 100 U/ml S1 nuclease (Sigma) in acetate buffer after ice-cold PBS wash, or an isotype control Ab (mouse IgM) or PBS was substituted for the anti-ssDNA mAb. Endogenous peroxidase was blocked using 3% H2O2 in PBS, and slides were treated with 0.1% BSA for 30 min. After rinsing, anti-ssDNA mAb was applied to sections for 15 min and washed, and biotin-conjugated rat anti-mouse IgM (Zymed, San Francisco, CA) was applied for another 15 min. After washing, ExtrAvidin-peroxidase (Sigma) was applied for 15 min. Sections were washed and developed with DAB (Sigma).
| Results and Discussion |
|---|
|
|
|---|
|
|
|
|
We hypothesize that if apoptosis is important in controlling the
responses of mucosal lymphoid cells to normal luminal Ags, then the
apoptosis would be reduced in an inflammatory microenvironment where,
in most cases, lymphocytes are activated. To test this hypothesis, we
determined apoptosis of lymphoid cells in the patients with colitis.
Apoptosis of T cells, plasma cells, and macrophages in LP was markedly
reduced in all tissue samples from the patients with colitis (Figs. 3
and 4
). This marked decrease in apoptosis did not appear to be due to
anti-inflammatory medication, because all patients had reduced
apoptosis regardless of type of therapy. In addition, there was no
correlation between disease activity or disease extent and degree of
apoptosis because most diseased mucosa had very low levels of T cell
apoptosis. Our data also showed that reduced T cell apoptosis was not
specific for UC, CD, or specific colitis and was seen in the inflamed
colon regardless of the etiology. Hence, reduced apoptosis may be a
factor in the immune dysregulation seen in IBD, but it may not play a
primary etiological role. The data from these patients contrasted with
results from murine colitis models, where increased T cell apoptosis
was found in inflamed mucosa (26, 27). This finding might
be due to the fact that there are few apoptotic LP T cells in normal
mouse mucosa.
The apoptosis of LP T cells could occur through CD95 and/or other receptors. It has been shown that most LP T cells isolated from uninvolved areas of resected colon carcinoma expressed CD95, as analyzed by flow cytometry (18). When LP cells were stimulated by CD2, the T cells also underwent apoptosis, which could be blocked by anti-CD95 Ab (17). However, unstimulated LP T cells underwent apoptosis in vitro, which could not be blocked by an inhibitory anti-CD95 Ab (17). Thus, the apoptosis of unstimulated LP T cells might be induced by an uncharacterized pathway, as shown in the in vitro experiment (17). It also has been shown that T cells isolated from areas of inflammation in CD, UC, and other inflammatory states were resistant to CD2-induced apoptosis, and that resistance was accompanied by elevated Bcl-2 levels (19). T cells grown from CD lesions were resistant to CD95- or NO-mediated apoptosis, with similarly increased Bcl-2:Bax ratios (20). Those data suggest that CD95 plays a role in inducing apoptosis in LP T cells; however, other receptors or pathways by which apoptosis is induced also might be involved.
It appears that the reduced apoptosis in IBD is a consequence of
inflammation rather than a cause of IBD, since it was also noted in
specific colitis. Thus, reduced apoptosis could be due to
proinflammatory cytokines that are abundantly present in the inflamed
mucosa. Many proinflammatory cytokines, such as IL-1, IL-6, IL-2,
IFN-
, and IL-15, are expressed in IBD (16, 28). In
particular, IL-15 might have an important effect in counteracting
apoptosis of LP cells, because it was shown that IL-15 was produced by
macrophages in inflamed mucosa of patients with IBD (28).
Bcl-2 expression can be induced as a result of signaling via the common
-chain of the IL-2 receptor, which serves as a signaling component
of the receptor for IL-2, IL-4, IL-7, and IL-15. Thus, IL-15 might
greatly enhance the expression of Bcl-2, which further enhances
resistance of LP T cells against induction of apoptosis.
In summary, we demonstrated that LP T cells underwent apoptosis in normal mucosa, which might have an important effects in maintaining the unresponsiveness of LP T cells to normal luminal Ags and the homeostasis of mucosal lymphoid tissue. The level of LP-cell apoptosis is greatly reduced in the inflamed colonic mucosa, which may contribute to the mucosal immune dysregulation noted in IBD.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 P.B., A.K., and D.D.S. contributed equally to this paper. ![]()
3 Address correspondence and reprint requests to Dr. Liang Qiao, Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153. ![]()
4 Abbreviations used in this paper: LP, lamina propria; AMCA, 7-amino-4-methylcoumarin-3-acetic acid; CD, Crohns disease; DAB, 3,3-diaminobenzidine; IBD, inflammatory bowel disease; UC, ulcerative colitis. ![]()
Received for publication October 25, 2000. Accepted for publication March 5, 2001.
| References |
|---|
|
|
|---|
secretion and T cell apoptosis. J. Immunol. 157:2348.[Abstract]
and IL-5. J. Immunol. 145:68.[Abstract]

T cells In SCID mice with colitis. Eur. J. Immunol. 26:3074.[Medline]
This article has been cited by other articles:
![]() |
T. T. MacDonald, A. DiSabatino, and J. N. Gordon Immunopathogenesis of Crohn's Disease JPEN J Parenter Enteral Nutr, July 1, 2005; 29(4_suppl): S118 - S125. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Zeissig, C Bojarski, N Buergel, J Mankertz, M Zeitz, M Fromm, and J D Schulzke Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor {alpha} antibody treatment Gut, September 1, 2004; 53(9): 1295 - 1302. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Hoffman-Goetz, J. Quadrilatero, J. Boudreau, and J. Guan Adrenalectomy in mice does not prevent loss of intestinal lymphocytes after exercise J Appl Physiol, June 1, 2004; 96(6): 2073 - 2081. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Marhaba, M. Bourouba, and M. Zoller CD44v7 interferes with activation-induced cell death by up-regulation of anti-apoptotic gene expression J. Leukoc. Biol., July 1, 2003; 74(1): 135 - 148. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Eaves-Pyles, H. R. Wong, K. Odoms, and R. B. Pyles Salmonella Flagellin-Dependent Proinflammatory Responses Are Localized to the Conserved Amino and Carboxyl Regions of the Protein J. Immunol., December 15, 2001; 167(12): 7009 - 7016. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Fitzpatrick, J. Wang, and T. Le Caffeic Acid Phenethyl Ester, an Inhibitor of Nuclear Factor-kappa B, Attenuates Bacterial Peptidoglycan Polysaccharide-Induced Colitis in Rats J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 915 - 920. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |